18F‐fluorodeoxyglucose positron emission tomography/computed tomography in the evaluation of clinically node‐negative non‐small cell lung cancer

One in four non‐small cell lung cancer (NSCLC) patients are diagnosed at an early‐stage. Following the results of the National Lung Screening Trial that demonstrated a survival benefit for low‐dose computed tomography screening in high‐risk patients, the incidence of early‐stage NSCLC is expected to increase. Use of 18F‐fluorodeoxyglucose positron emission tomography/computed tomography during initial diagnosis of these early‐stage lesions has been increasing. Traditionally, positron emission tomography/computed tomography scans have been utilized for mediastinal nodal staging and to rule out distant metastases in suspected early‐stage NSCLC. In clinically node‐negative NSCLC, the use of sublobar resection and selective lymph node dissection has been increasing as a therapeutic option. The higher rate of locoregional recurrences after limited resection and the significant incidence of occult lymph node metastases underscores the need to further stratify clinically node‐negative NSCLC in order to select patients for limited resection versus lobectomy with complete mediastinal lymph node dissection. In this report, we review the published data, and discuss the significance and potential role of 18F‐fluorodeoxyglucose positron emission tomography/computed tomography evaluation for clinically node‐negative NSCLC. Consequently, the literature review demonstrates that maximum standardized uptake value is a predictive factor for occult nodal metastasis with an accuracy of 55–77%. In addition, maximum standardized uptake value is a predictor for worse overall, as well as disease‐free, survival